


Next Gems Conference

October 2023

Strictly Private and Confidential

Shareholders' Structure & Key People



Key People





Umberto Perillo Chief Executive Officer

Mr. Perillo is the General Director and CEO of Svas Biosana Group since 2012. He joined the company in 1979, and has since dedicated himself to the growth and the strategic development of the group by optimizing its business model and by managing the most important recent acquisitions.

Andrea Efficace Mark Medical CEO & Group CFO

Mr. Efficace is CFO of Svasa Biosana Group since 2001, and CEO of Mark Medical since 2015. He joined the firm in 1998, and has since developed his professional career within the group. He's a certified chartered accountant and auditor.



Group Overview

Svas Biosana «At a Glance» Key Financial Highlights

Millions of Euro	2020A	2021A	2022A	H1 2022	H1 2023	
Net Revenues YoY A	76,0 <i>3,4%</i>	81,1 <i>6,6%</i>	97,2 19,9%	43,8	54,9 <i>25,3</i> %	
EBITDA EBITDA Margin	9,6 12,6%	10,6 13,1%	11,9 <i>12,2%</i>	5,7 13,0%	6,9 12,6%	
EBIT EBIT Margin	5,1 6,7%	5,7 7,1%	6,3 <i>6,4%</i>	3,1 7,1%	4,2 7,7%	
Net Income Margin %	2,5 3,3%	3,2 3,9%	3,6 3,7%	1,7 <i>3,9</i> %	2,3 4,2%	
NFP Equity	36,9 27,7	17,0 51,0	21,7 54,5		25,2 56,5	
Millions of Euro	1		ME-			
100,0 90,0		81,1	97,2			30,0%
80,0 70,0	76,6	01,1		+25,3% YoY		25,0%
60,0 50,0	12,6%	13,1%	12,2%	, 43,8	(54,9)	20,0% 15,0%
40,0 30,0 20,0						10,0%
10,0			2			5,0% 0,0%
0,0	2020A	2021A	2022A	H1 2022	H1 2023	0,0%
	-	Net Reve	enue 🗕	ebitda n	largin	

 FY 2022 consolidated Revenues include the revenue of Bormia d.o.o. (which was acquired in June 2022) of 2H 2022. Bormia d.o.o. 1H 2022 revenues, equal to €6,5m, are not included in FY 2022 consolidated revenues. SVAS Biosana Group ("SVAS", the "Company" or the "Group") is an Italian leading player in the medical devices and disposables sector, acting both as a manufacturer and as a distributor.

The Group was founded in Southern Italy in 1972 by Francesco Fausto Perillo, with the aim to provide medical devices in the area. Today, the Group is headquartered in Somma Vesuviana (Naples - NA) with three production plants located in Ottaviano (NA) and Somma Vesuviana (NA).

Medical devices are the core of Svas Biosana commercial offer. The Group counts more than 16,000 references, both with own and third parties brands.

The Group consists of three main companies:

- Svas Biosana: production and distribution of incontinence aids, cotton wool and personal care products, procedural packs (so-called custom packs), dressings, surgical instruments, as well as numerous other medical devices. It constitutes of three business lines: (i) Svas; (ii) Farmex; and (iii) Medical;
- Mark Medical Group: acquired by Svas Biosana in December 2015. It distributes medical items and medical-health devices supplied by top world producers exclusively in the Balkan Area (Slovenia, Croatia, Serbia and Bosnia-Herzegovina). Mark Medical is present in each of these countries in a widespread manner with subsidiaries dedicated to distribution and local assistance.
- Bormia Group: acquired by Svas Biosana in June 2022. Bormia Group is active in the distribution of specialized medical devices for cardiac surgery, anaesthesiology, critical care, endovascular procedures and neuroradiology in Slovenia, Croatia, Serbia and Bosnia.




3

October 2023


Market	Italian Market			Foreign Markets		
Business Line	FARMEX	MEDICAL	Svas			
Activity	Production and sale	Production and sale	Distribution and sale	Distribution and sale	Distribution and sale	
Products	Products for incontinence	Custom packs	Medical devices	Medical devices	Medical devices	
Activity	Production		Distribution			
Svas Biosana Investor Presentation						

Group Overview Geographical Presence and History



Svas Biosana Investor Presentation October 2023

Warehouses and




Production – Main products

Farmex



Adult Incontinence Aids



Medical



Custom Pack



Standard Dressings



Cotton Wool



Advanced Dressings



Surgical Suction Systems



Infusion and Drainage Devices



Distribution – Main products

Specialties









Peritoneal Dyalisis Products

Cardiac Surgery



Cardiopulmonary

TAVI

Radiology & Imaging



Contrast Media

Critical Care



Catheters and Infusion Disposable Endotracheal Tubes Systems







Orthopedic Implants

Arthroscopy Implants and Equipment

Cardiology





Guide Wires and Coronary Drug **Eluting Stent** Catheters *Robotics*



Robotic Magnetic Navigation System

Svas Biosana Investor Presentation October 2023



Laparoscopic Instruments



Advanced Medications



Infusion Lines



Surgical Instruments & Containers






Humidifiers

Hemostatic

Devices



Group Overview H1 2023 Sales Breakdown





(1) H1 2023 Aggregates Sales breakdown and respective incidence of each Business Line (computed as Net Revenues before infra-group elisions).


Group Overview

Investment Highlights and Market Dynamics

1. Rich and consolidated portfolio of products to satisfy chronic, medical and surgical healthcare needs



2. Qualified commercial structure and close relationship with medical operators generate additional value while creating high entry barriers





Source: (1) Eurostat Statistics, May 2021

(2) Future life expectancy in Europe taking into account the impact of smoking, obesity, and alcohol, Janseen et al, 2021

(3) Global Perspectives on Improving Chronic Disease Prevention and Management in Diverse Settings, Center for diseases control and prevention, April 2021

Men


(4) Global preventive healthcare market \$ 287 billion by 2027, iHealthcareAnalyst, March 2021


(5) Piano Nazionale di Ripresa e Resilienza, April 2021

Svas Biosana Investor Presentation October 2023

Financial Data Key Financial Highlights


Millions of Euro	2018A	2019A	2020A	2021A	2022A	H1 2022	H1 2023
Net Revenue <i>YoY ∆</i>	69,1	73,6 <i>6,4%</i>	76,0 <i>3,4%</i>	81,1 <i>6,6%</i>	97,2 19,9%	43,8	54,9 <i>25,3%</i>
EBITDA	8,3	9,2	9,6	10,6	11,9	5,7	6,9
EBITDA Margin	12,0%	12,5%	12,6%	<i>13,1%</i>	<i>12,2%</i>	13,0%	<i>12,6%</i>
EBIT	4,5	5,2	5,1	5,7	6,3	3,1	4,2
<i>EBIT Margin</i>	<i>6,5%</i>	7,0%	<i>6,7%</i>	7,1%	<i>6,4%</i>	<i>7,1%</i>	7,7%
Net Income	1,9	2,5	2,5	3,2	3,6	1,7	2,3
<i>Margin %</i>	<i>2,8%</i>	<i>3,4%</i>	3,3%	<i>3,9%</i>	<i>3,7%</i>	<i>3,9%</i>	<i>4,2%</i>
NFP	36,1	37,5	36,9	17,0	21,7		25,2
Equity	22,4	22,8	27,7	51,0	54,5		56,5
NFP /EBITDA	4,3x	4,1x	3,9x	1,6x	1,8x		-
NFP / Equity	1,6x	1,6x	1,3x	0,3x	0,4x		0,4x








* FY 2022 consolidated Revenues include the revenue of Bormia d.o.o. (which was acquired in June 2022) of 2H 2022. Bormia d.o.o. 1H 2022 revenues, equal to €6.5m, are not included in FY 2022 consolidated revenues.







60,0

40,0

20,0

0.0

H1 Net Revenues


43,8

H1 22

54,9

H1 23

Annex Group Structure



(1) Update to October 12th, 2023 Source: Group Management

Annex H1 Consolidated Income Statement

	30/06/2022	%	30/06/2023	%	Delta	%
Revenues from sales and services	43.843.886	100%	54.939.038	100%	11.095.152	25%
External costs	(33.165.592)	76%	(43.144.031)	79%	9.978.439	30%
Added Value	10.678.294	24%	11.795.007	21%	1.116.713	10%
Cost of labor	(5.822.602)	13%	(6.808.083)	12%	985.481	17%
Other revenues	(846.895)	2%	(1.943.038)	4%	1.096.143	129%
EBITDA	5.702.587	13%	6.929.962	13%	1.227.375	22%
Depreciations and Amortizations	(2.584.888)	6%	(2.691.740)	5%	106.852	4%
EBIT	3.117.699	7%	4.238.222	8%	1.120.523	36%
Interest expenses/incomes	(818.456)	2%	(914.401)	2%	95.945	12%
EBT	2.299.243	5%	3.323.821	6%	1.024.578	45%
Taxes	(583.351)	1%	(1.034.886)	2%	451.535	77%
Net Income	1.715.892	4%	2.288.935	4%	573.043	33%



Annex H1 Consolidated Balance Sheet

	31/12/2022	30/06/2023	Delta
	44,000,070	14.050.040	000.070
Net intangible fixed assets	11.023.670 26.209.159	11.350.040	326.370
Net tangible fixed assets		25.804.005	(405.154)
Equity investments and other financial fixed assets	229.980 37.462.809	110.179 37.264.224	(119.801)
Fixed capital	37.402.009	31.204.224	(198.585)
Inventories	29.821.907	31.648.962	1.827.055
Receivables from customers	38.995.140	41.934.105	2.938.965
Other credits	5.473.375	7.483.206	2.009.831
Prepayments and accrued income	878.560	869.824	(8.736)
Short-term operating activities	75.168.982	81.936.097	6.767.115
Payables to suppliers	28.198.447	28.591.000	392.553
Payables to suppliers Advances	20.190.447	20.591.000	(91.970)
Tax and social security payables (within the following year)	2.498.942	3.048.271	(91.970) 549.329
Other debts	2.070.471	2.745.307	674.836
Accrued liabilities and deferred income	1.408.220	894.635	(513.585)
Short-term operating liabilities	34.280.690	35.291.853	1.011.163
Net working capital	40.888.292	46.644.244	5.755.952
	40.000.292	40.044.244	5.155.352
Employee severance indemnity	1.927.528	1.987.359	59.831
Tax and social security payables (beyond the following year)	0	-	-
Other medium and long-term liabilities	249.560	232.595	(16.965)
Medium and long-term liabilities	2.177.088	2.219.954	42.866
Net Invested Capital	76.174.013	81.688.514	5.514.501
Equity	54.509.266	56.490.173	1.980.907
Net Financial Debt	21.664.747	25.198.341	3.533.594
Equity and Net Financial Debt	76.174.013	81.688.514	5.514.501



Svas Biosana Investor Presentation October 2023

Annex Consolidated Income Statement

	31/12/2021	%	31/12/2022	%	Delta	%
Revenues from sales and services	81.085.102	100,0%	97.226.932	100,0%	16.141.830	19,9%
External costs	60.383.563	74,5%	74.943.464	77,1%	14.559.901	24,1%
Added Value	20.701.539	25,5%	22.283.468	22,9%	1.581.929	7,6%
Cost of labor	11.022.402	13,6%	12.675.540	13,0%	1.653.138	15,0%
Other revenues	967.679	1,2%	2.289.652	2,4%	1.321.973	136,6%
EBITDA	10.646.816	13,1%	11.897.580	12,2%	1.250.764	11,7%
Depreciations and Amortizations	4.875.669	6,0%	5.640.213	5,8%	764.544	15,7%
EBIT	5.771.147	7,1%	6.257.367	6,4%	486.220	8,4%
Interest expenses/incomes	(1.752.985)	-2,2%	(1.600.587)	-1,6%	152.398	-8,7%
EBT	4.018.162	5,0%	4.656.780	4,8%	638.618	15,9%
Taxes	856.979	1,1%	1.085.305	1,1%	228.326	26,6%
Net Income	3.161.183	3,9%	3.571.475	3,7%	410.292	13,0%



Annex Consolidated Balance Sheet

	31/12/2021	31/12/2022	Delta
Net intangible fixed assets	10.749.503	11.023.670	274.167
Net tangible fixed assets	25.639.396	26.209.159	569.763
Equity investments and other financial fixed assets	159.786	229.980	70.194
Fixed capital	36.548.685	37.462.809	914.124
Inventories	25.126.150	29.821.907	4.695.757
Receivables from customers	31.827.089	38.995.140	7.168.051
Other credits	4.316.886	5.473.375	1.156.489
Prepayments and accrued income	743.824	878.560	134.736
Short-term operating activities	62.013.949	75.168.982	13.155.033
Payables to suppliers	23.336.838	28.198.447	4.861.609
Advances	72.468	104.610	32.142
Tax and social security payables (within the following year)	2.214.454	2.498.942	284.488
Other debts	1.489.860	2.070.471	580.611
Accrued liabilities and deferred income	1.196.077	1.408.220	212.143
Short-term operating liabilities	28.309.697	34.280.690	5.970.993
Net working capital	33.704.252	40.888.292	7.184.040
Employee severance indemnity	2.003.046	1.927.528	(75.518)
Tax and social security payables (beyond the following year)	25.000	0	(25.000)
Other medium and long-term liabilities	240.846	249.560	8.714
Medium and long-term liabilities	2.268.892	2.177.088	(91.804)
Net Invested Capital	67.984.045	76.174.013	8.189.968
Equity	50.965.741	54.509.266	3.543.525
Net Financial Debt	17.018.304	21.664.747	4.646.443
Equity and Net Financial Debt	67.984.045	76.174.013	8.189.968



Legal Disclaimer

For the purposes of this disclaimer, this presentation (the "Presentation") comprises the attached slides and any materials distributed at, or in connection with, the Presentation has been prepared by Svas Biosana S.p.A. (the "Company") solely for information and discussion purposes in connection with the admission of its shares ("Shares") on AIM Italia/Mercato Alternativo del Capitale organized and managed by Borsa Italiana S.p.A. ("AIM Italia") and, therefore, it is preliminary in nature.

The information provided in this Presentation is being furnished to you solely for your information on a confidential basis and, as such, has not been prepared with a view to public disclosure. Neither this document nor any copy thereof may be retained by you or reproduced, redistributed or passed on, in whole or in part, directly or indirectly, to any other person. Therefore, you undertake vis-à vis the Company (i) to keep secret any information of whatever nature relating to the Company and its affiliates including the fact that the information has been provided ("Information"); (ii) not to disclose any Information to anyone; (iii) not to make or allow any public announcements or communications concerning the Information; and (iv) to use reasonable endeavours to ensure that Information are protected against unauthorized access.

This Presentation is not an advertisement and does not constitute an offer or invitation to purchase or subscribe for any Share and neither it or any part of it shall form the basis of or be relied upon in connection with any contract or commitment or investments decision whatsoever. The Company has not prepared and will not prepare any prospectus for the purpose of the initial public offering of the Shares on Euronext Growth Milan("Private Placement"). Any decision to purchase or subscribe for Shares in connection with the Private Placement should be made independently of this Presentation. This Presentation does not constitute a recommendation regarding the Shares to be offered in the Private Placement. Therefore, nothing in this Presentation shall create any binding obligation or liability on the Company and its affiliates and any of their advisors or representatives.

This Presentation has been prepared solely for the use in connection with the possible Private Placement of Shares by the Company and other selling shareholders. The information contained in this document has not been independently verified and no representation or warranty express or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection with this Presentation.

THIS PRESENTATION IS ADDRESSED SOLELY TO ITALIAN QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 34-TER, PARAGRAPH 1, LETTER B), OF CONSOB REGULATION ON ISSUERS NO. 11971 OF MAY 14, 1999, AS SUBSEQUENTLY AMENDED AND TO CERTAIN OTHER PERSONS IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA") OTHER THAN ITALY (IN RESPECT OF WHICH THE REGULATION AND REQUIREMENTS REFERRED TO ABOVE APPLY) WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF ANNEX II, SECTION I, OF THE DIRECTIVE 2014/65/UE. THE PRIVATE PLACEMENT OF SHARES OF THE COMPANY, IF ANY, WILL BE MADE AS PART OF THE ADMISSION OF THE SHARES OF THE COMPANY ON EURONEXT GROWTH MILAN AND REPRESENTS A CONDITION OF SUCH ADMISSION TO TRADING. THIS DOCUMENT IS NOT ADDRESSED TO ANY MEMBER OF THE GENERAL PUBLIC NEITHER IN ITALY NOR ELSEWHERE. NO PUBLIC OFFERING OF SHARES IN ITALY OR ELSEWHERE WILL BE MADE.

The information contained in this Presentation is not for publication or distribution, directly or indirectly, in, nor does it constitute an offer to sell or a solicitation of offers to buy securities in the United States of America, Australia, Canada or Japan or any jurisdiction where such distribution is unlawful, (as such term is defined in Regulation S under the United States Securities Act of 1933, as amended ("Securities Act"). The distribution of this Presentation in other jurisdictions may be restricted by law. Persons into whose possession the content of this Presentation come should inform themselves about and observe any such restrictions. Any failure to comply with the restrictions set forth above may constitute a violation of applicable securities laws.

Neither this Presentation nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly in the United States of America, its territories or possessions, or distributed, directly or indirectly or indirectly in the United States or America, its territories or possessions, or distributed, directly or indirectly or indirectly or indirectly in the United States or America, its territories or possessions, or distributed, directly or indirectly or a solicitation of an offer to buy securities in the United States or any other jurisdiction. The Shares proposed to be offered by the Company does not intend to register any offering in the United States or conduct a public offering of securities in the United States.

Certain information contained in this Presentation may contain forward-looking statements which involve risks and uncertainties and are subject to change. In some cases, these forward-looking statements can be identified by the use of words such as "believe", "anticipate", "estimate", "target", "potential", "expect", "intend", "predict", "project", "could", "should", "may", "will", "plan", "aim", "seek" and similar expressions. The forecasts and forward-looking statements included in this document are necessarily based upon a number of assumptions and estimates that are inherently subject to significant business, operational, economic and competitive uncertainties and contingencies as well as assumptions with respect to future business decisions that are subject to change. By their nature, forward-looking statements involve known and unknown risks and uncertainties, because they relate to events, and depend on circumstances, that may or may not occur in the future. Furthermore, actual results may differ materially from those contained in any forward-looking statements speak only as at the date of this Presentation. The Company cautions you that forward looking-statements are not guarantees of future performance and that its actual financial position, business strategy, plans and objectives of management for future operations may differ materially from those results or developments may not be indicative of results or developments in future operations. In addition, even if the Company's control and company's financial position, business strategy, plans and objectives of management for future operations are consistent with the forward-looking statements contained in this Presentation, those results or developments may not be indicative of results or developments in future periods. The Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The information, views and opinions expressed in this Presentation are provided as of the date of this Presentation and remain subject to verification, completion and change without notice. Neither the Company and its affiliates, nor any of their advisors or representatives shall be obliged to furnish or to update any information or to notify or to correct any accuracies in any information.

You should not act or rely on, or make any use of the content of, this Presentation. This Presentation does not purport to be comprehensive. No representation or warranty, express or implied, is given by or on behalf of the Company or any of its directors, officers, advisers, agents or employees or any of their directors, officers, advisers, agents or employees thereof, or any other person as to the accuracy, truthfulness, fairness, materiality or completeness of the information or opinions contained in this Presentation. No liability whatsoever is accepted by the Company or any of its directors, officers, advisers, agents or employees thereof, nor any other person for any loss howsoever arising, directly, from any use of such information or opinions or otherwise arising in connection therewith. By accepting this Presentation you agree to be bound by the foregoing restrictions and you will treat as strictly private and confidential all such information and take all reasonable steps to preserve such confidentiality.

